BPC157.now
Regulatory Tracker

The formal FDA timeline

BPC-157-related substances are being evaluated through a structured, public FDA process. This tracker translates key milestones — from 2021 enforcement through the July 2026 PCAC hearing — into plain language.

  1. 2021

    FDA begins broader peptide enforcement and guidance clarification

    The FDA issued guidance and enforcement actions targeting compounded peptide products that had proliferated outside the 503A framework. This set the stage for formal substance-by-substance review of the peptide compounding landscape, including BPC-157-related substances.

  2. 2023

    FDA formally flags safety concerns around specific compounded peptides

    The FDA publicly identified safety signals associated with certain compounded peptide products — citing gaps in identity, purity, and potency data, and limited human clinical evidence. BPC-157-related substances were among those in the broader category under evaluation.

  3. 2025

    BPC-157-related substances nominated for 503A bulks list consideration

    Nominations requesting formal FDA evaluation of BPC-157-related substances for possible inclusion on the 503A bulks list were advanced through the public nomination process. This triggered the formal review pathway that leads to a PCAC discussion.

  4. 2026

    FDA schedules July 23 PCAC discussion for BPC-157-related substances

    The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to publicly discuss BPC-157-related bulk drug substances on July 23, 2026, as part of the 503A nomination process. The committee will review available evidence and produce a recommendation — not a binding rule.

  5. Current status

    Not FDA approved — and not offered through this website

    BPC-157 is not FDA approved as a drug. Compounded access is restricted under current rules. BPC157.now does not sell, prescribe, dispense, or ship BPC-157 or related products. This site is informational only.

  6. Future

    Any change requires formal rulemaking after advisory input

    A PCAC recommendation — favorable or not — is one input into a longer process: FDA notice of proposed rulemaking, public comment period, then a final rule. Any material change to BPC-157's compounding status will follow that sequence. We will summarize each step as it happens.

How to read this timeline

Each step shown above is part of a defined formal process. The July 23, 2026 PCAC meeting is not a final decision — it is an advisory discussion that produces a recommendation. The FDA may or may not follow that recommendation, and any change to BPC-157's compounding status would still require additional rulemaking steps after the meeting.

What the 503A process means

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. For a substance to be legally used by 503A compounders, it must either be commercially available as an approved drug, or appear on the FDA's 503A bulks list. BPC-157 is currently not on that list. The PCAC discussion is about whether it should be considered for addition.

After the meeting

Even a favorable PCAC recommendation does not mean immediate access. The FDA would then need to initiate a notice of proposed rulemaking, accept public comments, and issue a final rule — a process that typically takes months to years. We will cover each step as it happens.

Related coverage
FDA Schedules 2026 Review of BPC-157 Compounding Substances
Regulatory news
What the July 2026 FDA Advisory Meeting Could Mean
Analysis
What Is BPC-157?
Educational overview
FAQ: 503A and the PCAC Process
Common questions answered
Free Updates

Track every step of the FDA process.

Each rulemaking development explained within 24 hours — free.

BPC157.now does not sell, prescribe, or dispense BPC-157. Informational only.

BPC-157 is not FDA approved. Regulatory status may change. Nothing here is medical or legal advice.

Get Free BPC-157 Updates